BR112015015421A2 - métodos e composições para a administração de oxibutinina - Google Patents

métodos e composições para a administração de oxibutinina

Info

Publication number
BR112015015421A2
BR112015015421A2 BR112015015421A BR112015015421A BR112015015421A2 BR 112015015421 A2 BR112015015421 A2 BR 112015015421A2 BR 112015015421 A BR112015015421 A BR 112015015421A BR 112015015421 A BR112015015421 A BR 112015015421A BR 112015015421 A2 BR112015015421 A2 BR 112015015421A2
Authority
BR
Brazil
Prior art keywords
oxybutynin
administration
compositions
methods
Prior art date
Application number
BR112015015421A
Other languages
English (en)
Inventor
David A Byron
Robert Cook
Scott Fleming
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/728,706 external-priority patent/US9119777B2/en
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of BR112015015421A2 publication Critical patent/BR112015015421A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015015421A 2012-12-27 2013-12-12 métodos e composições para a administração de oxibutinina BR112015015421A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/728,706 US9119777B2 (en) 2008-05-30 2012-12-27 Methods and compositions for administration of oxybutynin
PCT/US2013/074759 WO2014105446A1 (en) 2012-12-27 2013-12-12 Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number Publication Date
BR112015015421A2 true BR112015015421A2 (pt) 2017-07-11

Family

ID=51021931

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015421A BR112015015421A2 (pt) 2012-12-27 2013-12-12 métodos e composições para a administração de oxibutinina

Country Status (15)

Country Link
EP (1) EP2938329A4 (pt)
JP (1) JP2016504358A (pt)
KR (1) KR20150100902A (pt)
CN (1) CN104955444A (pt)
AR (1) AR094287A1 (pt)
AU (1) AU2013368298B2 (pt)
BR (1) BR112015015421A2 (pt)
CA (1) CA2895955A1 (pt)
EA (1) EA201591218A1 (pt)
HK (2) HK1215396A1 (pt)
IL (1) IL239623A0 (pt)
MX (1) MX2015008333A (pt)
NZ (1) NZ628479A (pt)
UY (1) UY35230A (pt)
WO (1) WO2014105446A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190046493A1 (en) * 2016-02-25 2019-02-14 Hisamitsu Pharmaceutical Co., Inc. Liquid external preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371923A1 (en) * 1999-05-20 2000-11-30 Thomas P. Jerussi Methods for treatment of asthma using s-oxybutynin
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
EP1558563A1 (en) * 2002-10-29 2005-08-03 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
WO2010147631A1 (en) * 2009-06-16 2010-12-23 Wen Tan Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
EP2762133A1 (en) * 2010-04-01 2014-08-06 CHIESI FARMACEUTICI S.p.A. Process for preparing carrier particles for dry powders for inhalation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation

Also Published As

Publication number Publication date
IL239623A0 (en) 2015-08-31
EP2938329A4 (en) 2016-08-10
EP2938329A1 (en) 2015-11-04
EA201591218A1 (ru) 2015-11-30
HK1215396A1 (zh) 2016-08-26
AR094287A1 (es) 2015-07-22
UY35230A (es) 2015-01-30
MX2015008333A (es) 2015-11-09
CN104955444A (zh) 2015-09-30
HK1216843A1 (zh) 2016-12-09
CA2895955A1 (en) 2014-07-03
KR20150100902A (ko) 2015-09-02
JP2016504358A (ja) 2016-02-12
AU2013368298B2 (en) 2016-08-11
WO2014105446A1 (en) 2014-07-03
NZ628479A (en) 2016-06-24
AU2013368298A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
CL2014003386A1 (es) Métodos y composiciones para producción de biometano
CO6852076A2 (es) Composiciones farmacéuticas inhalables
DK2694038T3 (da) Farmaceutisk sammensætning
BR112014003052A2 (pt) composições farmacêuticas
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
BR112014025801A2 (pt) Composições para tinta
BR112013018875A2 (pt) métodos e composições para a preparação de noribogaína a partir de voacangina
DK2931970T4 (da) Cellulose-afledte sammensætninger
CO6930367A2 (es) Composiciones farmaceúticas
SMT201700110B (it) Composizione immunogena
BR112014000015A2 (pt) formulação
CO6940426A2 (es) Formulaciones farmacéuticas
CO6842021A2 (es) Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos
BR112014014232A2 (pt) composto e método para a preparação de um composto
DK2897594T3 (da) Farmaceutisk sammensætning
CO6950486A2 (es) Solución para administración oral
DK2502622T3 (da) Farmaceutisk formulering omfattende inositol
BR112013024413A2 (pt) compostos e métodos para a preparação de diarilpropanos
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
EP2867199A4 (en) STABLE COMPOSITIONS OF ESOTRERODINE
BR112015002646A2 (pt) composto e composição farmacêutica
BR112014029165A2 (pt) composição para a prevenção de dores de cabeça
BR112013023576A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
CR20130037A (es) Composición farmacéutica de liberación prolongada de trimetazidina
DK2745928T3 (da) Fremgangsmåde til emulsionsfremstilling

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.